Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis

Simple item page
dc.contributor.authorSalama, Hind Abdin
dc.contributor.authorJazieh, Abdul Rahman
dc.contributor.authorAlhejazi, Ayman Yahya
dc.contributor.authorAbsi, Ahmed A.
dc.contributor.authorAlshieban, Saeed
dc.contributor.authorAlzahrani, Mohsen
dc.contributor.authorAlaskar, Ahmed S.
dc.contributor.authorGmati, Giamal Edin
dc.contributor.authorDamlaj, Moussab B.
dc.contributor.authorAbuelgasim, Khadega Ahmed
dc.contributor.authorAlghamdi, Abdulrahman I.
dc.contributor.authorAlahmari, Bader
dc.contributor.authorAl Mugairi, Areej M.
dc.contributor.authorAl-Zahrani, Hazzaa Abdulla
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.authorMusa, M. O.H.
dc.contributor.authorGoyal, Gaurav
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentInternal Medicine
dc.contributor.departmentBone Marrow Transplantation (BMT) Program
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:20:42Z
dc.date.available2025-01-24T12:20:42Z
dc.date.issued2021
dc.description.abstractHistiocytic disorders are an exceptionally rare group of diseases with diverse manifestations and a paucity of approved treatments, thereby leading to various challenges in their diagnosis and management. With the discovery of novel molecular targets and the incorporation of targeted agents in the management of various adult histiocytic disorders, their management has become increasingly complex. In an attempt to improve the understanding of the clinical features and management of common adult histiocytic disorders (Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease, and hemophagocytic lymphohistiocytosis), we created this document based on existing literature and expert opinion. © 2020 Elsevier Inc.
dc.identifier.doihttps://doi.org/10.1016/j.clml.2020.08.007
dc.identifier.eid2-s2.0-85090854569
dc.identifier.pmid32943371
dc.identifier.urihttp://hdl.handle.net/10938/34366
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofClinical Lymphoma, Myeloma and Leukemia
dc.sourceScopus
dc.subjectBraf
dc.subjectCovid-19
dc.subjectMek
dc.subjectTargeted
dc.subjectTreatment
dc.subjectAdult
dc.subjectDrug therapy, combination
dc.subjectErdheim-chester disease
dc.subjectHistiocytosis, langerhans-cell
dc.subjectHistiocytosis, sinus
dc.subjectHumans
dc.subjectLymphohistiocytosis, hemophagocytic
dc.subjectTreatment outcome
dc.subjectAlemtuzumab
dc.subjectAlpha interferon
dc.subjectAnakinra
dc.subjectAzathioprine
dc.subjectB raf kinase inhibitor
dc.subjectBleomycin
dc.subjectBlinatumomab
dc.subjectCladribine
dc.subjectClofarabine
dc.subjectCobimetinib
dc.subjectCorticosteroid
dc.subjectCyclophosphamide
dc.subjectCyclosporine
dc.subjectDesmopressin
dc.subjectDexamethasone
dc.subjectDoxorubicin
dc.subjectEmapalumab
dc.subjectEtoposide
dc.subjectImmune checkpoint inhibitor
dc.subjectImmunoglobulin
dc.subjectLenalidomide
dc.subjectMercaptopurine
dc.subjectMethotrexate
dc.subjectMitogen activated protein kinase kinase inhibitor
dc.subjectPrednisolone
dc.subjectPrednisone
dc.subjectRapamycin
dc.subjectRituximab
dc.subjectRuxolitinib
dc.subjectSteroid
dc.subjectThalidomide
dc.subjectTocilizumab
dc.subjectTrametinib
dc.subjectVemurafenib
dc.subjectVinblastine
dc.subjectVincristine
dc.subjectAllogeneic hematopoietic stem cell transplantation
dc.subjectAutologous hematopoietic stem cell transplantation
dc.subjectClinical feature
dc.subjectClinical outcome
dc.subjectCoronavirus disease 2019
dc.subjectDiagnostic procedure
dc.subjectErdheim chester disease
dc.subjectGene mutation
dc.subjectHemophagocytic syndrome
dc.subjectHuman
dc.subjectImmunotherapy
dc.subjectInfection
dc.subjectLangerhans cell histiocytosis
dc.subjectMacrophage activation syndrome
dc.subjectMalignant neoplasm
dc.subjectMyeloablative conditioning
dc.subjectPregnancy
dc.subjectReduced intensity conditioning
dc.subjectReview
dc.subjectSinus histiocytosis
dc.subjectSmoking cessation
dc.subjectTreatment response
dc.subjectCombination drug therapy
dc.titleHighlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-6391.pdf
Size:
940 KB
Format:
Adobe Portable Document Format
Download

Collections

Specialized Clinical Programs and Services
Internal Medicine